APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotides

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Oligonucleotides are usually made up of 13 to 25 nucleotides and are designed to hybridize specifically to DNA or RNA sequences. Solid-phase clinical synthesis is used to manufacture these small bits of nucleic acid for use in polymerase chain reaction (PCR), DNA sequencing, library construction and artificial gene synthesis.

Selected research

Market Outlook & Growth Opportunities

Global Oligonucleotides Market Outlook and Growth Opportunities 2026

20 December 2025200 pages

Choose your research edition.

Industry ResearchOligonucleotides Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotides Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oligonucleotides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotides Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotides Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Oligonucleotides are usually made up of 13 to 25 nucleotides and are designed to hybridize specifically to DNA or RNA sequences. Solid-phase clinical synthesis is used to manufacture these small bits of nucleic acid for use in polymerase chain reaction (PCR), DNA sequencing, library construction and artificial gene synthesis.

Global Oligonucleotides key players include Integrated DNA Technologies, Agilent, Sigma-aldrich, Eurofins Genomics, L.G.C Biosearch Technologies, etc. Global top five manufacturers hold a share over 45%.

Read the full market overview

North America is the largest market, with a share over 35%, followed by Europe and China, both have a share over 35percent.

In terms of product, DNA Oligos is the largest segment, with a share over 65%. And in terms of application, the largest application is Research, followed by Pharmaceutical.

This report provides an overview of the global Oligonucleotides market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligonucleotides and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligonucleotides revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oligonucleotides market.

Oligonucleotides Segment by Company

Integrated DNA Technologies

Agilent

Sigma-aldrich

Eurofins Genomics

L.G.C Biosearch Technologies

Eurogentec S.A

Nitto Denko Avecia Inc

GenScript

BBI Life Sciences

GeneDesign

TriLink BioTechnologies

SGS DNA

LC Sciences

Twist Bioscience

Creative Biogene

General Biosystems

Oligonucleotides Segment by Type

DNA Oligos

RNA Oligos

Oligonucleotides Segment by Application

Pharmaceutical

Research

Diagnostic

Oligonucleotides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oligonucleotides status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oligonucleotides key companies, revenue, market share, and recent developments.

3. To split the Oligonucleotides breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oligonucleotides market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oligonucleotides significant trends, drivers, influence factors in global and regions.

6. To analyze Oligonucleotides competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotides industry.

Chapter 3: Detailed analysis of Oligonucleotides company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oligonucleotides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oligonucleotides in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oligonucleotides Industry Trends Table 2. Oligonucleotides Industry Drivers Table 3. Oligonucleotides Industry Opportunities and Challenges Table 4. Oligonucleotides Industry Restraints Table 5. Global Oligonucleotides Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oligonucleotides Revenue Share by Company (2021-2026) Table 7. Global Oligonucleotides Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oligonucleotides Key Company Manufacturing Base & Headquarters Table 9. Global Oligonucleotides Company, Product Type & Application Table 10. Global Oligonucleotides Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oligonucleotides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DNA Oligos Table 15. Significant Companies of RNA Oligos Table 16. Global Oligonucleotides Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Oligonucleotides Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Oligonucleotides Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Oligonucleotides Sales Value Share by Type (2021-2026) Table 20. Global Oligonucleotides Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical Table 22. Significant Companies of Research Table 23. Significant Companies of Diagnostic Table 24. Global Oligonucleotides Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Oligonucleotides Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Oligonucleotides Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Oligonucleotides Sales Value Share by Application (2021-2026) Table 28. Global Oligonucleotides Sales Value Share by Application (2027-2032) Table 29. Global Oligonucleotides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oligonucleotides Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Oligonucleotides Sales Value Share by Region (2021-2026) Table 32. Global Oligonucleotides Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Oligonucleotides Sales Value Share by Region (2027-2032) Table 34. Global Oligonucleotides Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oligonucleotides Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Oligonucleotides Sales Value Market Share by Country (2021-2026) Table 37. Global Oligonucleotides Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Oligonucleotides Sales Value Market Share by Country (2027-2032) Table 39. Integrated DNA Technologies Company Information Table 40. Integrated DNA Technologies Business Overview Table 41. Integrated DNA Technologies Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Integrated DNA Technologies Oligonucleotides Product Portfolio Table 43. Integrated DNA Technologies Recent Development Table 44. Agilent Company Information Table 45. Agilent Business Overview Table 46. Agilent Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Agilent Oligonucleotides Product Portfolio Table 48. Agilent Recent Development Table 49. Sigma-aldrich Company Information Table 50. Sigma-aldrich Business Overview Table 51. Sigma-aldrich Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sigma-aldrich Oligonucleotides Product Portfolio Table 53. Sigma-aldrich Recent Development Table 54. Eurofins Genomics Company Information Table 55. Eurofins Genomics Business Overview Table 56. Eurofins Genomics Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Eurofins Genomics Oligonucleotides Product Portfolio Table 58. Eurofins Genomics Recent Development Table 59. L.G.C Biosearch Technologies Company Information Table 60. L.G.C Biosearch Technologies Business Overview Table 61. L.G.C Biosearch Technologies Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. L.G.C Biosearch Technologies Oligonucleotides Product Portfolio Table 63. L.G.C Biosearch Technologies Recent Development Table 64. Eurogentec S.A Company Information Table 65. Eurogentec S.A Business Overview Table 66. Eurogentec S.A Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eurogentec S.A Oligonucleotides Product Portfolio Table 68. Eurogentec S.A Recent Development Table 69. Nitto Denko Avecia Inc Company Information Table 70. Nitto Denko Avecia Inc Business Overview Table 71. Nitto Denko Avecia Inc Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Nitto Denko Avecia Inc Oligonucleotides Product Portfolio Table 73. Nitto Denko Avecia Inc Recent Development Table 74. GenScript Company Information Table 75. GenScript Business Overview Table 76. GenScript Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. GenScript Oligonucleotides Product Portfolio Table 78. GenScript Recent Development Table 79. BBI Life Sciences Company Information Table 80. BBI Life Sciences Business Overview Table 81. BBI Life Sciences Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. BBI Life Sciences Oligonucleotides Product Portfolio Table 83. BBI Life Sciences Recent Development Table 84. GeneDesign Company Information Table 85. GeneDesign Business Overview Table 86. GeneDesign Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GeneDesign Oligonucleotides Product Portfolio Table 88. GeneDesign Recent Development Table 89. TriLink BioTechnologies Company Information Table 90. TriLink BioTechnologies Business Overview Table 91. TriLink BioTechnologies Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 92. TriLink BioTechnologies Oligonucleotides Product Portfolio Table 93. TriLink BioTechnologies Recent Development Table 94. SGS DNA Company Information Table 95. SGS DNA Business Overview Table 96. SGS DNA Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 97. SGS DNA Oligonucleotides Product Portfolio Table 98. SGS DNA Recent Development Table 99. LC Sciences Company Information Table 100. LC Sciences Business Overview Table 101. LC Sciences Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 102. LC Sciences Oligonucleotides Product Portfolio Table 103. LC Sciences Recent Development Table 104. Twist Bioscience Company Information Table 105. Twist Bioscience Business Overview Table 106. Twist Bioscience Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 107. Twist Bioscience Oligonucleotides Product Portfolio Table 108. Twist Bioscience Recent Development Table 109. Creative Biogene Company Information Table 110. Creative Biogene Business Overview Table 111. Creative Biogene Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 112. Creative Biogene Oligonucleotides Product Portfolio Table 113. Creative Biogene Recent Development Table 114. General Biosystems Company Information Table 115. General Biosystems Business Overview Table 116. General Biosystems Oligonucleotides Sales (Million MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 117. General Biosystems Oligonucleotides Product Portfolio Table 118. General Biosystems Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Oligonucleotides Product Image Figure 2. Global Oligonucleotides Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotides Market Size (2021-2032) & (US$ Million) Figure 4. Global Oligonucleotides Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DNA Oligos Image Figure 8. RNA Oligos Image Figure 9. Global Oligonucleotides Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Oligonucleotides Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Oligonucleotides Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical Image Figure 13. Research Image Figure 14. Diagnostic Image Figure 15. Global Oligonucleotides Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oligonucleotides Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oligonucleotides Sales Value Share by Application (2021-2032) Figure 18. Global Oligonucleotides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Oligonucleotides Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 21. North America Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 27. South America Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Oligos
  • RNA Oligos
Applications
  • Pharmaceutical
  • Research
  • Diagnostic
Companies covered
  • Integrated DNA Technologies
  • Agilent
  • Sigma-aldrich
  • Eurofins Genomics
  • L.G.C Biosearch Technologies
  • Eurogentec S.A
  • Nitto Denko Avecia Inc
  • GenScript
  • BBI Life Sciences
  • GeneDesign
  • TriLink BioTechnologies
  • SGS DNA
  • LC Sciences
  • Twist Bioscience
  • Creative Biogene
  • General Biosystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oligonucleotides Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oligonucleotides Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oligonucleotides Market Dynamics
  1. 2.1 Oligonucleotides Industry Trends
  2. 2.2 Oligonucleotides Industry Drivers
  3. 2.3 Oligonucleotides Industry Opportunities and Challenges
  4. 2.4 Oligonucleotides Industry Restraints
3 Oligonucleotides Market by Company
  1. 3.1 Global Oligonucleotides Company Revenue Ranking in 2025
  2. 3.2 Global Oligonucleotides Revenue by Company (2021-2026)
  3. 3.3 Global Oligonucleotides Company Ranking (2024-2026)
  4. 3.4 Global Oligonucleotides Company Manufacturing Base and Headquarters
  5. 3.5 Global Oligonucleotides Company Product Type and Application
  6. 3.6 Global Oligonucleotides Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oligonucleotides Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oligonucleotides Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oligonucleotides Market by Type
  1. 4.1 Oligonucleotides Type Introduction
  2. 4.1.1 DNA Oligos
  3. 4.1.2 RNA Oligos
  4. 4.2 Global Oligonucleotides Sales Value by Type
  5. 4.2.1 Global Oligonucleotides Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Oligonucleotides Sales Value by Type (2021-2032)
  7. 4.2.3 Global Oligonucleotides Sales Value Share by Type (2021-2032)
5 Oligonucleotides Market by Application
  1. 5.1 Oligonucleotides Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Research
  4. 5.1.3 Diagnostic
  5. 5.2 Global Oligonucleotides Sales Value by Application
  6. 5.2.1 Global Oligonucleotides Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oligonucleotides Sales Value by Application (2021-2032)
  8. 5.2.3 Global Oligonucleotides Sales Value Share by Application (2021-2032)
6 Oligonucleotides Regional Value Analysis
  1. 6.1 Global Oligonucleotides Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oligonucleotides Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oligonucleotides Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oligonucleotides Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oligonucleotides Sales Value (2021-2032)
  7. 6.3.2 North America Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oligonucleotides Sales Value (2021-2032)
  10. 6.4.2 Europe Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oligonucleotides Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oligonucleotides Sales Value (2021-2032)
  16. 6.6.2 South America Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oligonucleotides Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oligonucleotides Sales Value Share by Country, 2025 VS 2032
7 Oligonucleotides Country-level Value Analysis
  1. 7.1 Global Oligonucleotides Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oligonucleotides Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oligonucleotides Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oligonucleotides Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oligonucleotides Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oligonucleotides Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oligonucleotides Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oligonucleotides Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oligonucleotides Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oligonucleotides Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oligonucleotides Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oligonucleotides Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oligonucleotides Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oligonucleotides Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oligonucleotides Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oligonucleotides Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oligonucleotides Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oligonucleotides Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oligonucleotides Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oligonucleotides Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oligonucleotides Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oligonucleotides Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oligonucleotides Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oligonucleotides Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oligonucleotides Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oligonucleotides Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oligonucleotides Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oligonucleotides Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oligonucleotides Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oligonucleotides Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oligonucleotides Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oligonucleotides Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oligonucleotides Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Integrated DNA Technologies
  2. 8.1.1 Integrated DNA Technologies Company Information
  3. 8.1.2 Integrated DNA Technologies Business Overview
  4. 8.1.3 Integrated DNA Technologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Integrated DNA Technologies Oligonucleotides Product Portfolio
  6. 8.1.5 Integrated DNA Technologies Recent Developments
  7. 8.2 Agilent
  8. 8.2.1 Agilent Company Information
  9. 8.2.2 Agilent Business Overview
  10. 8.2.3 Agilent Oligonucleotides Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Agilent Oligonucleotides Product Portfolio
  12. 8.2.5 Agilent Recent Developments
  13. 8.3 Sigma-aldrich
  14. 8.3.1 Sigma-aldrich Company Information
  15. 8.3.2 Sigma-aldrich Business Overview
  16. 8.3.3 Sigma-aldrich Oligonucleotides Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sigma-aldrich Oligonucleotides Product Portfolio
  18. 8.3.5 Sigma-aldrich Recent Developments
  19. 8.4 Eurofins Genomics
  20. 8.4.1 Eurofins Genomics Company Information
  21. 8.4.2 Eurofins Genomics Business Overview
  22. 8.4.3 Eurofins Genomics Oligonucleotides Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eurofins Genomics Oligonucleotides Product Portfolio
  24. 8.4.5 Eurofins Genomics Recent Developments
  25. 8.5 L.G.C Biosearch Technologies
  26. 8.5.1 L.G.C Biosearch Technologies Company Information
  27. 8.5.2 L.G.C Biosearch Technologies Business Overview
  28. 8.5.3 L.G.C Biosearch Technologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  29. 8.5.4 L.G.C Biosearch Technologies Oligonucleotides Product Portfolio
  30. 8.5.5 L.G.C Biosearch Technologies Recent Developments
  31. 8.6 Eurogentec S.A
  32. 8.6.1 Eurogentec S.A Company Information
  33. 8.6.2 Eurogentec S.A Business Overview
  34. 8.6.3 Eurogentec S.A Oligonucleotides Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eurogentec S.A Oligonucleotides Product Portfolio
  36. 8.6.5 Eurogentec S.A Recent Developments
  37. 8.7 Nitto Denko Avecia Inc
  38. 8.7.1 Nitto Denko Avecia Inc Company Information
  39. 8.7.2 Nitto Denko Avecia Inc Business Overview
  40. 8.7.3 Nitto Denko Avecia Inc Oligonucleotides Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nitto Denko Avecia Inc Oligonucleotides Product Portfolio
  42. 8.7.5 Nitto Denko Avecia Inc Recent Developments
  43. 8.8 GenScript
  44. 8.8.1 GenScript Company Information
  45. 8.8.2 GenScript Business Overview
  46. 8.8.3 GenScript Oligonucleotides Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GenScript Oligonucleotides Product Portfolio
  48. 8.8.5 GenScript Recent Developments
  49. 8.9 BBI Life Sciences
  50. 8.9.1 BBI Life Sciences Company Information
  51. 8.9.2 BBI Life Sciences Business Overview
  52. 8.9.3 BBI Life Sciences Oligonucleotides Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BBI Life Sciences Oligonucleotides Product Portfolio
  54. 8.9.5 BBI Life Sciences Recent Developments
  55. 8.10 GeneDesign
  56. 8.10.1 GeneDesign Company Information
  57. 8.10.2 GeneDesign Business Overview
  58. 8.10.3 GeneDesign Oligonucleotides Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GeneDesign Oligonucleotides Product Portfolio
  60. 8.10.5 GeneDesign Recent Developments
  61. 8.11 TriLink BioTechnologies
  62. 8.11.1 TriLink BioTechnologies Company Information
  63. 8.11.2 TriLink BioTechnologies Business Overview
  64. 8.11.3 TriLink BioTechnologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  65. 8.11.4 TriLink BioTechnologies Oligonucleotides Product Portfolio
  66. 8.11.5 TriLink BioTechnologies Recent Developments
  67. 8.12 SGS DNA
  68. 8.12.1 SGS DNA Company Information
  69. 8.12.2 SGS DNA Business Overview
  70. 8.12.3 SGS DNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  71. 8.12.4 SGS DNA Oligonucleotides Product Portfolio
  72. 8.12.5 SGS DNA Recent Developments
  73. 8.13 LC Sciences
  74. 8.13.1 LC Sciences Company Information
  75. 8.13.2 LC Sciences Business Overview
  76. 8.13.3 LC Sciences Oligonucleotides Revenue and Gross Margin (2021-2026)
  77. 8.13.4 LC Sciences Oligonucleotides Product Portfolio
  78. 8.13.5 LC Sciences Recent Developments
  79. 8.14 Twist Bioscience
  80. 8.14.1 Twist Bioscience Company Information
  81. 8.14.2 Twist Bioscience Business Overview
  82. 8.14.3 Twist Bioscience Oligonucleotides Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Twist Bioscience Oligonucleotides Product Portfolio
  84. 8.14.5 Twist Bioscience Recent Developments
  85. 8.15 Creative Biogene
  86. 8.15.1 Creative Biogene Company Information
  87. 8.15.2 Creative Biogene Business Overview
  88. 8.15.3 Creative Biogene Oligonucleotides Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Creative Biogene Oligonucleotides Product Portfolio
  90. 8.15.5 Creative Biogene Recent Developments
  91. 8.16 General Biosystems
  92. 8.16.1 General Biosystems Company Information
  93. 8.16.2 General Biosystems Business Overview
  94. 8.16.3 General Biosystems Oligonucleotides Revenue and Gross Margin (2021-2026)
  95. 8.16.4 General Biosystems Oligonucleotides Product Portfolio
  96. 8.16.5 General Biosystems Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst